Updated NeoVax Cancer Vaccine Shows Improved Immune Response in Melanoma Trial

Local women step out in support of Dana-Farber

WEST SPRINGFIELD — A local fundraising team led by two neighbors and friends is seeking donations in support of their cause as they prepare to participate in the 2025 Jimmy Fund Walk to raise money for the Dana-Farber Cancer Institute.West Springfield residents and friends Deb Callahan and Kris Towse have joined forces to participate in the annual fundraising walk to support the Dana-Farber Cancer Institute and will host two additional fundraise…

Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria

The complex gastrointestinal environment and the intestinal epithelial barrier constrain the design and effectiveness of orally administered tumour vaccines. Here we show that outer membrane vesicles (OMVs) fused to a tumour antigen and produced in the intestine by ingested genetically engineered bacteria function as effective tumour vaccines in mice. We modified Escherichia coli to express, under the control of a promoter induced by the monosac…

Updated NeoVax cancer vaccine shows improved immune response in melanoma trial

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform.

Modified personalized cancer vaccine generates powerful immune response

Results of a Dana-Farber Cancer Institute-initiated phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax personalized cancer vaccine called NeoVaxMI is safe, feasible, and improves the vaccine-specific immune response compared to previous trials of the platform.

Dana-Farber’s Trial Shows Improved Immune Response With Vaccine - Data Intelligence

For the trial, the feasibility and safety of the vaccine were planned without formal clinical outcome evaluations. Credit: KomootP/Shutterstock. Findings from a Phase I trial initiated by Dana-Farber Cancer Institute have demonstrated that the NeoVax personalised cancer vaccine’s updated formula and delivery, NeoVaxMI,is not only feasible and safe but also elicits an improved vaccine-specific immune response in melanoma patients. The trial’s sub…